Empliciti

Active Ingredient(s): Elotuzumab
FDA Approved: * November 30, 2015
Pharm Company: * BRISTOL MYERS SQUIBB
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Empliciti Overview

Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma.[1] It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor.[1] Administration of elotuzumab is d...

Read more Empliciti Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Elotuzumab

Recent Empliciti Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Elotuzumab
  • Injection: 300mg, 400mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Empliciti: (2 results)

Sorted by National Drug Code
  • 0003-2291 Empliciti 300 mg Intravenous Injection, Powder, Lyophilized, for Solution by E.r. Squibb & Sons, L.L.C.
  • 0003-4522 Empliciti 400 mg Intravenous Injection, Powder, Lyophilized, for Solution by E.r. Squibb & Sons, L.L.C.

Other drugs which contain Elotuzumab or a similar ingredient: (1 result)